Macrogenicsincis A Biopharmaceutical Company Based In Rockvillemarylandfounded In 2000It Specializes In The Discoverydevelopmentmanufacturingand Commercialization Of Monoclonal Antibody Based Therapeutics For Cancer Treatmentthe Company Employs Over 240 Professionals And Is Publicly Traded On Nasdaq Under The Ticker Mgnx Macrogenics Focuses On Developing Antibody Therapeutics Using Proprietary Technology Platformsits Key Products Include Margenzaa Margetuximab An Fda Approved Therapy For Metastatic Breast Cancerand Tzielda Teplizumab Approved For Type 1 Diabetesthe Company Also Utilizes Its Dartaplatform For Creating Bispecific Antibodies And Engages In Strategic Collaborations With Global Pharmaceutical Firms For Co Development And Commercializationmacrogenics Maintains In House Manufacturing Capabilities To Support Its Therapeutic Production And Continues To Advance Its Clinical Pipeline Through Targeted Partnerships
No conferences found for this company.
| Company Name | Macrogenics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
